Trefoil Therapeutics

09/28/2023

It’s our 10 year anniversary, and we’ve come a long way!

We are proud of the research and development of TTHX1114, our lead investigational candidate, and continue our steadfast work to develop solutions for people with corneal dysfunctions.

Learn more about our pipeline: https://trefoiltherapeutics.com/products/

09/21/2023

Trefoil was formed on a simple hypothesis: harness the capabilities of fibroblast growth factors (FGFs) to solve a wide range of anterior and posterior corneal diseases.

Our Chief Executive Officer David Eveleth and Chief Medical Officer Mark Packer, MD, recently sat down with Cataract & Refractive Surgery Today to explore the path that led to the discovery of the role of FGFs, and the process behind TTHX1114.

Read more: https://crstoday.com/articles/2023-aug/to-protect-and-heal

Trefoil Therapeutics was formed on a simple hypothesis: harness the capabilities of fibroblast growth factors (FGFs) to solve a wide range of anterior and posterior corneal diseases.

09/18/2023

🌟

Jessica is a seasoned scientist specializing in novel molecular techniques. She spearheads the research of TTHX1114 to explore its regenerative, protective and vision-restoring properties.

In addition to her Leaders of Influence in Life Sciences recognition from the San Diego Business Journal, Jessica’s recent accomplishments include research that contributed to the submission of an Investigational New Drug Application to the FDA, poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and several published studies in peer-reviewed journals.

We’re proud to have Jessica’s leadership and research contributions as we develop our lead investigational candidate, TTHX1114.

09/14/2023

💭 Cataracts are a leading cause of blindness.

However, can have troubling side effects, such as oxidative stress, which can lead to vision impairment and even blindness.

Our investigational therapy, TTHX1114, is designed to provide protective benefits to corneal endothelial cells and prevent oxidative-induced cell death.

Learn more: https://trefoiltherapeutics.com/products/

09/06/2023

Congratulations to Dr. Michael Blaber, Trefoil co-founder, on his retirement from Florida State University (FSU).

Dr. Blaber joined FSU in 1994 as an assistant professor in chemistry. In the years since, he pioneered the research of Fibroblast Growth Factor 1 (FGF1) in his lab, securing 5 patents for FGF1 mutations and contributing to more than 185 published studies.

Dr. Blaber paved the road in biopharmaceutical proteins, and we thank him for his remarkable contributions to the discovery and development of FGF1. While he’s retiring from FSU, we look forward to his continued contributions on Trefoil’s Scientific Advisory Board.

09/01/2023

: by age 80, more than half of all Americans either have or have had cataract surgery. Following surgery, some people experience swelling, also known as edema, in the endothelium that can slow or stop the healing process.

Positive results from a Phase 2 study show that TTHX1114, our lead investigational candidate, protects and supports the healing of the corneal endothelium following cataract surgery.

Learn more: https://trefoiltherapeutics.com/trefoil-therapeutics-lead-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs-annual-meeting/

08/18/2023

Check out this article in pharmaphorum from our CEO David Eveleth exploring the challenge of cell death following and how our investigational candidate, TTHX1114, could help speed up recovery.

Read here: https://pharmaphorum.com/rd/improving-treatment-high-risk-cataract-surgery

Improving treatment for high-risk cataract surgery R&D Cataracts rank among the most prevalent age-related ailments. The condition, which is caused by the degradation of proteins in the lens of our eyes, creates a progressively opaque mass in the centre of a person’s vision, blurring, and obscurin...

08/07/2023

DYK: Ferroptosis is a complication of cell death in high-risk patients recovering from cataract surgery, leading to delayed healing and low visual acuity.

Recent research indicates that TTHX1114 shows promise in reversing the ferroptosis process.

Learn more: https://www.trefoiltherapeutics.com/

08/02/2023

– Did you know that Ralph Bradshaw, our Scientific Advisory Board Chair and Professor Emeritus at University of California, Irvine, was one of the four co-founders of Trefoil along with three of his former students.

“He has approached these entrepreneurial activities with integrity, knowledgeable insights, and enthusiasm, making working with him a consistently rewarding and enjoyable experience, not only as a co-founder but also as an independent scientific collaborator,” said Kenneth Thomas, co-founder and advisor to Trefoil.

Read more here: https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fba.2022-00088

07/26/2023

Researcher Spotlight 🌟
At the recent meeting, Thomas Tremblay, Vice President of Clinical Development, presented data that demonstrates the importance of identifying and better understanding the factors that could influence the outcomes in clinical trials.

People with Fuchs Endothelial Corneal Dystrophy often have other comorbid conditions that could affect the results of clinical trials, therefore it’s imperative that we attempt to design better and more efficient trials that minimize the number of people required and obtain more accurate results.

07/24/2023

Congratulations to Jessica Weant, Director of Research Development, on being named a Leader of Influence in Life Sciences by San Diego Business Journal. Jessica has contributed immensely to the of our lead candidate, TTHX1114, and mentored several early career researchers in their academic and professional goals.

Read more:https://images.sdbj.com/wp-content/uploads/2023/07/SDBJ-Leaders-of-Influence-in-Life-Sciences-Honorees-2023.pdf

07/18/2023

– Drug Discovery & Development published an article from our CEO David Eveleth on the potential benefits of our investigational therapy, TTHX1114, for improving corneal edema treatment.

Check it out: https://www.drugdiscoverytrends.com/novel-therapy-shows-promise-in-improving-corneal-edema-treatment/

Trefoil Therapeutics' TTHX1114 shows promise in addressing corneal edema, a common complication after cataract surgery in trials.